Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Minshall

Physician Assistant, Medical Oklahoma City, OK Physician Assistant

NPI 1487784765 CMS profile 11207924

13301 N Meridian Ave Ste 201, Oklahoma City, OK 73120

Open in the dashboard

General payments

$11,182

568 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Minshall of Oklahoma City, OK is reported in the CMS Open Payments database as having received $11,182 across 568 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,386 153
2024 General $3,173 121
2023 General $1,961 94
2022 General $1,839 101
2021 General $1,824 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Minshall
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jennifer Minshall were reported at $2,386. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jennifer Minshall Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,824 $156 $41–$563 $132
2022 $1,839 $185 $55–$649 $149
2023 $1,961 $199 $58–$717 $160
2024 $3,173 $206 $62–$740 $164
2025 $2,386 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. LEO Pharma Inc. $1,521 55 payments
  2. UCB, Inc. $1,305 69 payments
  3. Regeneron Healthcare Solutions, Inc. $1,044 35 payments
  4. Novartis Pharmaceuticals Corporation $991 73 payments
  5. Genzyme Corporation $897 49 payments
  6. Pfizer Inc. $781 52 payments
  7. Lilly USA, LLC $613 21 payments
  8. E.R. Squibb & Sons, L.L.C. $560 16 payments
  9. Janssen Biotech, Inc. $499 18 payments
  10. AbbVie, Inc. $483 29 payments
  11. Other $2,486 151 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,890 560 payments
  2. Consulting Fee $788 1 payment
  3. Education $504 7 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $986 59 payments
  2. DUPIXENT Inflammation And Immunology $807 27 payments
  3. Bimzelx $726 35 payments
  4. ADBRY $644 44 payments
  5. CIBINQO $623 40 payments
  6. TREMFYA $599 15 payments
  7. COSENTYX Immunology $548 48 payments
  8. Cimzia $545 33 payments
  9. TALTZ $479 18 payments
  10. COSENTYX Dermatology $476 32 payments
  11. Other $3,660 233 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

801

Median for Physician Assistant: 241

Drug cost

$176,552

Median for Physician Assistant: $4,110

Branded share of claims

6.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 41 $153,455
Clobetasol Propionate Generic 276 $11,146
Fluocinonide Generic 95 $3,792
Fluorouracil Generic 50 $3,577
Ketoconazole Generic 114 $1,593
Clindamycin Phosphate Generic 29 $775
Triamcinolone Acetonide Generic 94 $765
Imiquimod Generic 16 $459
Valacyclovir Valacyclovir Hcl Brand 13 $310
Minocycline Hcl Generic 12 $286

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$126,810

Medicare's payments for the services billed

Medicare patients

924

Average age 74

Services billed

3,475

513 women, 411 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 52%
Ischemic heart disease 34%
Chronic kidney disease 27%
Diabetes 26%
Depression 19%
Cancer 17%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $256
  • GENZYME CORPORATION $159
$415 41 —
Bimzelx
  • UCB, Inc. $308
$308 — —
RINVOQ
  • AbbVie, Inc. $252
$252 — —
ADBRY
  • LEO Pharma Inc. $215
$215 — —
Otezla
  • Amgen Inc. $205
$205 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

568 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record